Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy

URN to cite this document:: urn:nbn:de:bvb:355-epub-455279
DOI to cite this document:: 10.5283/epub.45527

Grimm, Jonathan ; Peschel, Georg ; Müller, Martina ; Schacherer, Doris ; Wiest, Reiner ; Weigand, Kilian

; Buechler, Christa

Preview

License: Creative Commons Attribution No Derivatives 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 15 Apr 2021 14:24

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipoprotein (LDL) levels increase rapidly upon DAA treatment. Proprotein convertase subtilisin/kexin 9 (PCSK9) induces degradation of the hepatic LDL receptor and thereby elevates serum LDL. The aim of this study was to determine serum PCSK9 concentrations during and after DAA therapy to identify ...